Abstract:Background: The purpose of the present study was to investigate the use of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor(VEGF) levels to monitor the treatment response to transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Methods: A total of 41 consecutive HCC patients underwent TACE were enrolled into this study. The serum levels of HIF-1 alpha and VEGF were measured using enzyme-linked immunosorbent assays (ELISAs) 1 day before, and 1, 7 and 28 days after TACE therapy. The overall tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors criteria. Patients with a complete response or partial response comprised the responding group, whereas thaw with stable disease or progressive disease comprised the non-responding group. The differences in serum HIF-1 alpha and VEGF levels before and after TACE therapy were subjected to analysis of nonparametric test, while correlations between serum HIF-1 alpha and VEGF levels were examined using Pearson's correlation analysis. Receiver-operating characteristic (ROC) curve was applied to analyze the evaluation value of factors for the response of TACE on the treatment of HCC. P<0.05 was considered statistically significant. Results: In the present study, the serum levels of HIF-1 alpha correlated positively with the serum levels of VEGF 1 day before TACE (r = 0.546, P = 0.000). The levels of HIF-1 alpha and VEGF 1 day before, and 1, 7 and 28 days after TACE were significantly different, respectively (chi(2)= 90.688, P = 0.000 and chi(2)= 45.585 , P = 0.000). The levels of the HIF-1 alpha and VEGF increased markedly on day 1 and 7 after TACE and recovered to the pre-TACE level on day 28 after TACE. The levels of serum VEGF in responder group 28 days after TACE were significantly lower than those in non-responder group (Z = 2.774, P = 0.006), but the difference of HIF-1 alpha levels between the two groups was not significant (Z = 1.905, P = 0.057). ROC curve analysis indicated that the sensitivity and specificity were 76.9% and 78.6%, when the threshold value was set at VEGF = 254.5 pg/ml, for predicting the response of TACE in patients with HCC; the corresponding area under the curve (AUC) was 0.772, respectively. Conclusions: The levels of both HIF-1 alpha and VEGF in patients with HCC after TACE exhibit dynamic changes. However, HIF-1 alpha and VEGF may be insufficient for predicting tumor response to TACE treatment.

Expression of VEGF,integrin-αV and MVD in Viable Residual Tumor Tissues from Large Hepatocellular Carcinoma after TACE

Effect of transcatheter arterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor in cervical squamous cell carcinoma

Assessment of Hepatocellular Carcinoma Undergoing Trans-Catheter Arterial Chemoembolization with Functional Magnetic Resonance Imaging

Intratumoral microvessel density and expression of vascular endothelial growth factor in hepatocellular carcinoma after chemoembolization

Evaluation of the Curative Effect of Transcatheter Arterial Chemoembolization Via Hepatic Artery Combined with Percutaneous Ethanol Injection for the Treatment of Primary Hepatocellular Carcinoma

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

Vascular endothelial growth factor receptor-2 and its phosphorylated state in cancerous and peri-cancerous tissues of hepatocellular carcinoma after transcatheter arterial chemoembolization

PATHOLOGICAL STUDY OF RESECTED SPECIMENS OF RESECTABLE LARGE HEPATOCELLULAR CARCINOMA AFTER TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION

Expression of PCNA and Nm23-H1/ndpk in Hepatocellular Carcinoma Following Transcatheter Arterial Chemoembolization Therapy

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

The Changes of HIF-1α and VEGF Expression after TACE in Patients with Hepatocellular Carcinoma

Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Involving Microvascular Invasion.

Impact of Serum Vascular Endothelial Growth Factor on Prognosis in Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization

The influence of postoperative TACE on the survival time and prognosis in hepatocellular carcinoma patients after liver resection

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma

HIF-1α and VEGF Levels for Monitoring Hepatocellular Carcinoma Treatment Response to Transcatheter Arterial Chemoembolization

Postoperative Adjuvant Transcatheter Arterial Chemoembolization Should Be Considered Selectively in Patients Who Have Hepatocellular Carcinoma with Microvascular Invasion.

Effect of Transarterial Chemoembolization As Postoperative Adjuvant Therapy for Intermediate-Stage Hepatocellular Carcinoma with Microvascular Invasion: a Multicenter Cohort Study.

Neovascularization in Survival Cancerous Tissue after Transcatheter Arterial Chemoembolization in Rabbits Bearing VX2 Liver Tumor

CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE.

MMPs and VEGF were increased by irradiation combined with interventional treatment in the rabbit VX 2 liver tumor